Recruiting Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC NCT05950139 Conditions ALK Fusion Protein Expression, Bronchial Neoplasms, Carcinoma, Bronchogenic, +9 more Locations Johns Hopkins University — Baltimore, Maryland, United States View Trial Details
Not Yet Recruiting A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer NCT05186506 Conditions ALK Fusion Protein Expression, Adjuvant Therapy, Bronchial Neoplasms, +10 more Locations Not specified View Trial Details
